← Back to Search

Procedure

VITALYST System for Heart Disease (VITALYST EFS Trial)

N/A
Recruiting
Research Sponsored by Boston Scientific Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured through 72 hours or hospital discharge (whichever comes first) after the intervention/procedure
Awards & highlights
No Placebo-Only Group

Summary

"This trial is testing a new system called VITALYST to see if it is safe and feasible for use in patients undergoing a high-risk heart procedure called percutaneous coronary intervention."

Who is the study for?
The VITALYST EFS is for adults aged 18 to less than 90 who need a non-emergency procedure (HR-PCI) for heart vessel blockages and have reduced heart pump function. They must agree to the study's terms, be evaluated by a heart team including a surgeon, and not be in an emergency situation.
What is being tested?
This trial tests the VITALYST System during elective high-risk procedures to open blocked arteries of the heart. It aims to assess how feasible and safe this system is when used in patients with serious coronary artery disease.
What are the potential side effects?
While specific side effects are not listed here, interventions like HR-PCI can typically include risks such as bleeding, blood vessel damage, irregular heartbeat, or reactions related to device implantation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured through 72 hours or hospital discharge (whichever comes first) after the intervention/procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured through 72 hours or hospital discharge (whichever comes first) after the intervention/procedure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinical Success

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: High Risk PCI PatientsExperimental Treatment1 Intervention
Patients undergoing non-emergent, high-risk percutaneous coronary interventions

Find a Location

Who is running the clinical trial?

Boston Scientific CorporationLead Sponsor
744 Previous Clinical Trials
857,808 Total Patients Enrolled
~13 spots leftby Nov 2025